BioGeneration Ventures
BioGeneration Ventures B.V. is a venture capital firm specializing in academic spinouts, seed capital, growth capital, and early stage investments including series A and series B rounds. The firm seeks to invest in the next generation of life sciences companies with a focus on healthcare, immuno-oncology, heart disease drugs, therapeutics, medical devices, diagnostics, novel food applications, pharmaceutical, food, agriculture and industrial biotechnology. It prefers to invest in companies based in Europe with a focus on Benelux, Netherlands, Belgium, and Germany. It prefers to invest between EUR5 million and EUR6 million. It is an active shareholder and board member in its portfolio companies. It exits its investment within 5-7 years. BioGeneration Ventures B.V. was founded in 2006 and is based in Naarden, Netherlands.
Region
Sector
34 past transactions
Cristal Delivery B.V.
Venture Round in 2014
Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.
Scenic Biotech B.V.
Series A in 2017
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.
Mellon Medical B.V.
Series B in 2017
Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular and layered structures.
Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland.
Azafaros B.V.
Seed Round in 2018
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Dunad Therapeutics
Series A in 2021
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
NorthSea Therapeutics
Series B in 2020
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
arGEN-X
Series A in 2010
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
NorthSea Therapeutics
Series A in 2017
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Mucosis
Venture Round in 2016
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection.
Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Confo Therapeutics
Series A in 2019
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Escalier Biosciences
Series B in 2018
Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands with offices in Nijmegen, The Netherlands and Encinitas, California.
Acerta Pharma, LLC
Seed Round in 2013
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.
Complement Therapeutics
Series A in 2023
Scenic Biotech B.V.
Series A in 2022
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.
River BioMedics
Seed Round in 2022
arGEN-X
Series A in 2009
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Acerta Pharma, LLC
Series A in 2013
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.
Complement Therapeutics
Seed Round in 2022
NorthSea Therapeutics
Series C in 2021
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Dezima Pharma
Venture Round in 2013
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.
Mucosis
Series A in 2007
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection.
Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Citryll BV
Series B in 2020
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Complement Therapeutics
Seed Round in 2021
Catalym
Series B in 2020
CATALYM GmbH develops immuno-oncology therapeutics. The company was founded in 2016 and is based in Munich, Germany.
VarmX
Series A in 2018
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Cristal Delivery B.V.
Venture Round in 2017
Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.
Synaffix BV
Series A in 2014
Synaffix BV is a biotechnology company that develops antibody-drug conjugate (ADC) technology platforms for oncology. It offers GlycoConnect, a site-specific antibody conjugation technology that modifies naturally-occurring glycan anchor points that exist on various antibodies to facilitate site-specific and stable conjugation of potent anti-cancer molecules. The company also offers HydraSpace, a payload-enhancing linker technology that is used to reduce ADC aggregation potential, increase payload solubility, improve conjugation efficiency, and enable higher drug loading. In addition, it offers a metal-free click chemistry that is applicable across pharma, biotech, and academic groups. The company was founded in 2010 and is based in Oss, the Netherlands.
Azafaros B.V.
Series A in 2020
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Mucosis
Venture Round in 2014
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection.
Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
FlexGen B.V.
Private Equity Round in 2009
FlexGen is an innovative biotech company based in Leiden, the Netherlands. FlexGen is a spin-off from Leiden University Medical Centre (LUMC) and Dutch Space (part of EADS) and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules.
FlexGen commercializes the FlexArrayer, a bench-top instrument for custom microarray and oligopool synthesis.
FlexGen works at the forefront of innovative microarray and oligopool applications.
Lanthio Pharma
Series A in 2012
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.
VarmX
Seed Round in 2017
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
VarmX
Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Medisse
Venture Round in 2009
Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers.
Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.
